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Psoriatic arthritis
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Abstract

Objective To examine patterns of tumour necrosis factor
inhibitor (TNFi) use in TNFi-naive and TNFi-experienced
patients with psoriatic arthritis (PsA) in the USA.
Methods All patients aged ≥18 years with PsA enrolled
in the Corrona Psoriatic Arthritis/Spondyloarthritis
Registry who initiated a TNFi (index therapy)
between March 2013 and January 2017 and had ≥1
follow-up visit were included. Times to and rates of
discontinuation/switch of the index TNFi were compared
between TNFi-naive and TNFi-experienced cohorts.
Patient demographics and disease characteristics at the
time of TNFi initiation (baseline) were compared between
cohorts and between patients who continued versus
discontinued their index TNFi by the first follow-up visit
within each cohort.
Results This study included 171 TNFi-naive and 147
TNFi-experienced patients (total follow-up, 579.2 personyears). Overall, 75 of 171 TNFi-naive (43.9%) and 80 of
147 TNFi-experienced (54.4%) patients discontinued their
index TNFi; 33 of 171 (19.3%) and 48 of 147 (32.7%),
respectively, switched to a new biologic. TNFi-experienced
patients had a shorter time to discontinuation (median,
20 vs 27 months) and were more likely to discontinue
(p=0.03) or switch (p<0.01) compared with TNFi-naive
patients. Among those who discontinued, 49 of 75 TNFinaive (65.3%) and 59 of 80 TNFi-experienced (73.8%)
patients discontinued by the first follow-up visit; such
patients showed a trend towards higher baseline disease
activity compared with those who continued.
Conclusions The results of this real-world study can help
inform treatment decisions when selecting later lines of
therapy for patients with PsA.

Introduction
Psoriatic arthritis (PsA) is a chronic,
immune-mediated rheumatic disease that
affects the musculoskeletal system, skin and

Key messages
What is already known about this subject?
►► Patients with psoriatic arthritis (PsA) often cycle

among tumour necrosis factor inhibitors (TNFis),
although data regarding the effectiveness of TNFi
cycling in clinical practice are inconclusive.
►► As biologics with alternative mechanisms of action
become available, it is important to understand the
persistence of TNFi use among TNFi-naive versus
TNFi-experienced patients and to characterise those
who continue versus discontinue their TNFis in order
to better inform treatment decisions for patients with
PsA.

What does this study add?
►► In this real-world analysis of US patients with PsA,

TNFi-experienced patients were more likely to discontinue or switch their index TNFi and had a shorter time to discontinuation compared with TNFi-naive
patients.
►► Patients who discontinued their index TNFi by the
first follow-up visit were more likely to be female
and showed a trend toward higher disease activity and worse patient-reported outcomes compared
with those who continued.

How might this impact on clinical practice?
►► These results may help inform treatment decisions

when selecting later lines of therapy for patients
with PsA.

nails.1 2 The symptoms of PsA are diverse and
may include axial skeletal disorders, nail and
skin changes, peripheral joint inflammation,
enthesitis and/or dactylitis.1–3 Patients with
PsA also have increased risk of developing a
number of comorbidities, including hypertension, hyperlipidaemia, cardiovascular disease,
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type 2 diabetes mellitus, Crohn’s disease, chronic obstructive pulmonary disease and depression, compared with the
general population.3–5 PsA is frequently associated with
psoriasis; an estimated 6%–42% of patients with psoriasis
have or will develop PsA,1 6 7 while studies suggest that
10%–40% of patients with psoriasis may have undiagnosed
PsA.8 9 The clinical heterogeneity of symptoms and potential burden of comorbidities can complicate the diagnosis
and treatment of PsA.3 10
Symptomatic treatment of PsA typically includes
non-steroidal anti-inflammatory drugs and corticosteroids.11 12 For patients with active PsA, disease-modifying
antirheumatic drugs, such as methotrexate or biologics,
may be necessary for disease control.11 12 Tumour
necrosis factor inhibitors (TNFis) have traditionally
been the first choice of biologic agent for patients with
refractory PsA.12–14 The efficacy and safety of TNFis
for the treatment of PsA have been demonstrated in
clinical trials.15–19 However, previous real-world studies
have shown that approximately 20%–40% of patients
with PsA who initiate a TNFi may discontinue due to
primary or secondary loss of efficacy, adverse effects
or other reasons.20 21 For patients who do not respond
to a particular TNFi, switching to another TNFi may
be effective and is a treatment option based on the
published literature and experience in clinical practice.12–14 21
European registry studies have shown mixed outcomes
with respect to the effectiveness and persistence of
TNFis in patients with PsA who received first-line
versus second-line TNFis, with some studies showing
better outcomes in patients who switched TNFis and
others showing no difference between treatment
lines or poorer response and persistence in patients
who initiated a second-line versus first-line TNFi.20–25
A prospective, observational study of patients with
PsA in southern Sweden showed moderate improvement in disease activity following the first switch of
TNFi, but poorer response in patients who switched a
second time.26 A previous study using US claims data
showed that patients who initiated a first-line TNFi had
longer persistence compared with those who initiated
a second-line TNFi; however, this study did not assess
patient factors that may be associated with persistence,
such as disease activity and patient-reported outcomes
(PROs) at initiation, or reasons for discontinuation.27
Few studies have characterised patients with PsA who
continue versus discontinue a TNFi based on line of TNFi
therapy in real-world settings in the USA. A previous study
of patients with PsA enrolled in the US-based Corrona
Registry observed greater persistence with TNFi therapy
among biologic-naive patients compared with biologic-experienced patients; baseline patient characteristics associated with non-persistence included high disease activity
and longer disease duration in both patient populations
as well as prior non-biologic disease-modifying antirheumatic drug use and greater skin involvement among
biologic-experienced patients.28 However, this study was
2

conducted in patients enrolled in the Corrona Registry
who initiated a TNFi between October 2002 and March
2013, prior to the approval of biologics with alternative
mechanisms of action (MOAs) for the treatment of PsA
and before the launch of the Corrona Psoriatic Arthritis/
Spondyloarthritis (PsA/SpA) Registry (March 2013),
which focuses on a unique cohort of patients with PsA/
SpA. The introduction of newer biologics with alternative MOAs has provided additional treatment options for
first-line biologic therapy and for patients who have an
inadequate response to a TNFi. The availability of these
biologics with new MOAs may change biologic prescribing
patterns and patient preferences in clinical practice;
thus, reassessment of treatment patterns is needed as the
therapeutic landscape continues to expand.
To better inform decisions regarding choice of
biologic therapy for patients with PsA in clinical practice, it is important to understand the persistence of
TNFi use among TNFi-naive patients compared with
those who cycle among multiple TNFis and to characterise those who continue versus discontinue a first
versus second or later line of TNFi therapy. Therefore, the objective of this study was to examine patient
characteristics and patterns of TNFi use in TNFi-naive
versus TNFi-experienced patients with PsA enrolled in
the US Corrona PsA/SpA Registry.
Methods
Study population
The Corrona PsA/SpA Registry (NCT02530268) is a
large, independent, prospective, observational cohort of
patients diagnosed with PsA or SpA by a rheumatologist.
The registry includes patients recruited by 43 participating rheumatologists from 35 private and academic
practice sites across 22 states in the USA. Follow-up data
collection occurs approximately every 6 months using
questionnaires completed by patients and their treating
rheumatologists. As of December 2017, data on 2526
patients with PsA/SpA had been collected. The Corrona
PsA/SpA Registry includes information on 10 767 patient
visits and approximately 5928 patient-years of follow-up
observation time, with a mean duration of follow-up of
3.0 years (median, 3.3 years).
This study included all patients aged ≥18 years
enrolled in the Corrona PsA/SpA Registry who were
diagnosed with PsA, initiated a TNFi (index therapy)
between March 2013 and January 2017 and had ≥1
follow-up visit after TNFi initiation. Patients were
assigned to a cohort based on prior biologic use (TNFi
naive: no prior TNFi or other biologic; TNFi experienced: ≥1 prior TNFi without use of a prior non-TNFi
biologic) and followed until discontinuation of the
index biologic or the end of the study period. Patients
within the TNFi-naive and TNFi-experienced cohorts
were stratified by continuation or discontinuation of
the index TNFi by the first follow-up visit. Patients in
the continued group were those who were still receiving
Mease PJ, et al. RMD Open 2019;5:e000880. doi:10.1136/rmdopen-2018-000880
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(serious, minor or fear of side effects), social reasons
(cost, patient preference or frequency of administration), doing well (remission or similar events) and
other reasons.

Figure 1 Patient disposition. The total follow-up period
included 579.2 person-years, with a mean (SD) follow-up
of 21.9 (9.6) months and median (IQR) follow-up of 23.0
(15.0) months. Patients included in the discontinued groups
were those who switched to a new biologic (TNFi naive,
n=33; TNFi experienced, n=48) or who discontinued without
switching (TNFi naive, n=42; TNFi experienced, n=32). PsA,
psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour
necrosis factor inhibitor.

the index TNFi at the first follow-up visit; patients in the
discontinued group were those who switched from the
index TNFi to a different TNFi or who discontinued the
index TNFi without switching by the first follow-up visit.
For patients who switched TNFis during follow-up, only
the first TNFi initiation was included in the analysis.
All participating investigators were required to obtain
full board approval for conducting non-interventional
research involving human subjects with a limited data set.
All research was conducted in compliance with the Helsinki
Declaration of 1964 and all later amendments. All registry
subjects were required to provide written informed consent
and authorisation prior to participating.
Outcomes and assessments
Data were collected using questionnaires completed by
patients and their treating rheumatologists at office visits.
Data collected at the time of TNFi initiation (baseline)
included patient demographics, clinical characteristics,
laboratory measurements, disease activity measures and
PROs; baseline characteristics were compared between
TNFi-naive and TNFi-experienced patients and between
those who continued versus discontinued their index
TNFi by the first follow-up visit.
Time to discontinuation (with or without switching)
and time to switch to a new biologic over the total
follow-up period were reported for patients who
discontinued their index TNFi in the overall population and in the TNFi-naive and TNFi-experienced
cohorts. Provider-reported reasons for discontinuation
or switch of the index TNFi were collected for patients
who discontinued at any point during follow-up and for
those who discontinued by the first follow-up visit in the
overall population and in the TNFi-naive and TNFi-experienced cohorts. Potential reasons for discontinuation or switch included lack of effect (inadequate
response or failure to maintain response), side effects
Mease PJ, et al. RMD Open 2019;5:e000880. doi:10.1136/rmdopen-2018-000880

Statistical analysis
Baseline patient demographics, clinical characteristics,
disease activity measures and PROs were compared
between TNFi-naive and TNFi-experienced patients
and between those who continued versus discontinued
their index TNFi by the first follow-up visit within each
cohort using the χ2 or Fisher exact test for categorical
variables and the two-sample t-test or Wilcoxon rank-sum
test for continuous variables. Categorical variables were
summarised using frequency counts and percentages;
continuous variables were summarised by the number
of observations, mean, SD, median and IQR. Reasons
for discontinuation or switch of the index TNFi were
summarised descriptively. Time to discontinuation (with
or without switching) and time to switch of the index
TNFi were assessed by Kaplan-Meier analysis for the
overall population and in the TNFi-naive and TNFi-experienced cohorts. Log-rank tests were performed to test
the equality of survivor functions between the TNFi-naive
and TNFi-experienced cohorts. Statistical analyses were
performed using Stata V.14.
Results
Patient population and baseline characteristics
Of the 1804 patients with PsA enrolled in the Corrona
PsA/SpA Registry, 395 initiated a TNFi during the study
period (March 2013–January 2017); 318 had ≥1 follow-up
visit and were included in the analyses (TNFi naive,
n=171 (53.8%); TNFi experienced, n=147 (46.2%))
(figure 1). Overall, the mean (SD) age was 53.6 (13.7)
years, 56.8% of patients were female and the majority of
patients (90.6%) were white (table 1). TNFi-experienced
patients had significantly longer PsA disease duration
(mean (SD), 13.3 (10.0) vs 9.5 (9.7) years; p<0.01) and
a higher proportion had a history of prednisone use
(27.9% vs 17.5%; p=0.03) compared with TNFi-naive
patients (table 1).
TNFi-naive patients had lower average lateral lumbar
flexion (mean (SD), 13.5 (5.0) vs 21.8 (16.9) cm; p=0.04),
lower baseline patient global assessment scores (mean (SD),
41.1 (28.0) vs 52.2 (29.2); p<0.01) and higher EQ-5D scores
(mean (SD), 0.74 (0.21) vs 0.70 (0.21); p=0.02) compared
with TNFi-experienced patients; a higher proportion of
TNFi-naive patients had minimal disease activity compared
with TNFi-experienced patients (39.3% vs 27.4%; p=0.04)
(table 2). TNFi-experienced patients had greater Spondyloarthritis Research Consortium of Canada Enthesitis
Index scores among those with enthesitis (mean (SD), 4.6
(3.9) vs 2.9 (2.3)), higher pain (mean (SD), 47.3 (29.5)
vs 40.9 (29.6)) and Health Assessment Questionnaire
for the Spondyloarthropathies (mean (SD), 0.73 (0.66)
vs 0.85 (0.68) scores, and a higher percentage of work
3
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Table 1 Baseline demographics and clinical characteristics of TNFi-naive and TNFi-experienced patients with PsA overall
and in those who continued versus discontinued their index TNFi by the first follow-up visit

Characteristic
Age, mean (SD),
years

Total
population
(N=318)

TNFi naive

53.6 (13.7)

53.0 (15.2)

Overall
(n=171)

TNFi experienced
Continued
(n=122)

Discontinued Overall
(n=49)
(n=147)

Continued
(n=88)

Discontinued
(n=59)

53.6 (16.2)

51.5 (12.2)

54.3 (11.6)

54.0 (11.8)

54.9 (11.4)

Female, n (%)

179 (56.8)

94 (55.3)

64 (52.5)

30 (62.5)

85 (58.6)

45 (51.7)

40 (69.0)*

White, n (%)

288 (90.6)

159 (93.0)

112 (91.8)

47 (95.9)

129 (87.8)

78 (88.6)

51 (86.4)

32.4 (7.6)

32.1 (8.0)

32.1 (8.1)

32.1 (8.0)

32.7 (7.1)

32.0 (7.3)

33.6 (6.8)

BMI, mean (SD), kg/
m2

BMI (in kg/m2) classification, n (%)
 Normal/
underweight
(<25.0)

41 (13.8)

27 (17.2)

20 (17.9)

7 (15.6)

14 (9.9)

11 (13.1)

3 (5.3)

 Overweight (25.0
to <30.0)

83 (27.9)

40 (25.5)

24 (21.4)

16 (35.6)

43 (30.5)

29 (34.5)

14 (24.6)

174 (58.4)

90 (57.3)

68 (60.7)

22 (48.9)

84 (59.6)

44 (52.4)

40 (70.2)

249 (78.5)

136 (79.5)

93 (76.2)

43 (87.8)

113 (77.4)

70 (80.5)

43 (72.9)

 Medicare

21 (6.6)

12 (7.0)

11 (9.0)

1 (2.0)

9 (6.2)

3 (3.5)

6 (10.2)

 Medicaid

21 (6.6)

12 (7.0)

9 (7.4)

3 (6.1)

9 (6.2)

6 (6.9)

3 (5.1)

 Medicare+private

21 (6.6)

8 (4.7)

7 (5.7)

1 (2.0)

13 (8.9)

8 (9.2)

5 (8.5)

5 (1.6)

3 (1.8)

2 (1.6)

1 (2.0)

9.5 (9.7)

9.7 (9.8)

8.8 (9.6)

13.3 (10.0)† 14.1 (9.4)

 Obese (≥30.0)
Insurance type, n (%)
 Private

 None
 Disease duration,
mean (SD), years

11.2 (10.0)

2 (1.4)

0

2 (3.4)
12.1 (10.9)

History of comorbid conditions, n (%)
 Diabetes mellitus

43 (13.5)

21 (12.3)

15 (12.3)

6 (12.2)

22 (15.0)†

13 (14.8)

9 (15.3)

 Cardiovascular
disease‡

45 (14.2)

18 (10.5)

15 (12.3)

3 (6.1)

27 (18.4)

17 (19.3)

10 (17.0)

 Any cancer§

25 (7.9)

13 (7.6)

10 (8.2)

3 (6.1)

12 (8.2)

7 (8.0)

5 (8.5)

 Serious infection¶

25 (7.9)

12 (7.0)

8 (6.6)

4 (8.2)

13 (8.8)

8 (9.1)

5 (8.5)

 Current MTX use,
n (%)

157 (49.4)

92 (53.8)

63 (51.6)

29 (59.2)

65 (44.2)

40 (45.5)

25 (42.4)

 History of
prednisone use,
n (%)

71 (22.3)

30 (17.5)

22 (18.0)

8 (16.3)

41 (27.9)†

30 (34.1)

11 (18.6)

 Current prednisone
use, n (%)

27 (8.5)

12 (7.0)

8 (6.6)

4 (8.2)

15 (10.2)

8 (9.1)

7 (11.9)

*P<0.05 for the comparison between patients who continued versus discontinued their index TNFi within the TNFi-naive or TNFi-experienced
cohort.
†P<0.05 for the comparison between the overall populations of TNFi-naive and TNFi-experienced patients.
‡Combined histories of myocardial infarction, acute coronary syndrome, coronary artery disease, congestive heart failure, peripheral artery
disease, cardiac revascularisation procedure, ventricular arrhythmia, cardiac arrest, unstable angina, stroke, transient ischaemic attack,
pulmonary embolism, carotid artery disease, deep venous thrombosis or other cardiovascular event.
§Excludes non-melanoma of the skin.
¶Includes infections that led to hospitalisation or intravenous antibiotics: joint/bursa, cellulitis, sinusitis, diverticulitis, sepsis, pneumonia,
bronchitis, gastroenteritis, meningitis, urinary tract, upper respiratory tract or infection of other specified site.
BMI, body mass index; MTX, methotrexate; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.

time missed (mean (SD), 9.8% (24.0%) vs 2.6% (7.8%);
p=0.03) compared with TNFi-naive patients, although only
the difference in percentage of work time missed reached
statistical significance (table 2).
4

Time to discontinuation/switch of index TNFi during total
follow-up
The total follow-up was 579.2 person-years; the mean
(SD) and median (IQR) total follow-up were 21.9 (9.6)
Mease PJ, et al. RMD Open 2019;5:e000880. doi:10.1136/rmdopen-2018-000880

Enthesitis, n (%)

2.2 (3.8)

Swollen joint count (0–66)
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2.0 (0.8)
4.3 (2.7)
3.3 (2.7)

ASDAS-CRP

BASDAI (0–10)

BASFI (0–10)

45.6 (28.5)

Patient-reported fatigue (VAS 0–100)

0.72 (0.21)
70.6 (45.4)

EQ-5D (0–1)
EQ VAS

0.74 (0.21)
70.9 (20.8)

0.73 (0.66)

111 (73.5)

214 (75.6)
0.78 (0.67)

40 (26.5)

151 (88.3)

43.9 (28.4)

40.9 (29.6)

41.1 (28.0)

4.9 (8.7)

21.9 (21.9)

17.6 (15.8)

3.8 (9.0)

2.7 (1.3)

10.7 (10.0)

3.1 (2.8)

4.1 (2.8)

2.1 (0.9)

59 (39.3)

13.5 (5.0)

0.6 (2.0)

2.2 (3.7)

4.2 (8.4)

2.3 (2.3)

21 (12.3)

2.9 (2.3)

35 (20.5)

0.76 (0.19)
73.1 (19.1)

0.67 (0.63)

73 (69.5)

32 (30.5)

105 (86.1)

42.5 (28.3)

37.6 (28.9)

38.2 (27.8)

5.3 (9.6)

20.4 (21.3)

17.6 (16.6)

3.0 (7.2)

2.4 (1.0)

9.2 (7.6)

3.0 (2.7)

4.0 (2.7)

2.0 (0.9)

45 (42.1)

14.7 (4.9)

0.8 (2.3)

1.8 (2.8)

3.0 (4.9)

1.8 (1.7)

13 (10.7)

2.5 (1.5)

24 (19.7)

0.70 (0.24)
65.6 (23.8)

0.87 (0.73)

38 (82.6)

8 (17.4)

46 (95.8)

47.3 (28.6)

49.5 (29.8)**

48.2 (27.6)**

3.8 (5.7)

25.4 (23.2)

17.4 (13.3)

6.0 (12.8)

3.5 (1.7)**

14.1 (13.6)**

3.4 (2.9)

4.5 (2.8)

2.3 (1.0)

14 (32.6)

9.8 (3.4)

0.2 (0.5)

3.2 (5.1)

7.3 (13.4)

3.1 (3.0)

8 (16.3)

3.8 (3.4)

11 (22.5)

0.70 (0.21)§
70.2 (63.1)

0.85 (0.68)

103 (78.0)

29 (22.0)

132 (89.8)

47.6 (28.7)

47.3 (29.5)

52.2 (29.2)§

4.9 (10.6)

20.8 (21.1)

16.7 (15.6)

1.5 (3.2)

2.8 (1.1)

11.9 (9.2)

3.6 (2.6)

4.5 (2.6)

1.9 (0.7)

34 (27.4)§

21.8 (16.9)§

3.2 (5.6)

2.2 (4.0)

5.7 (10.0)

2.6 (1.9)

16 (10.9)

4.6 (3.9)

38 (25.9)

Overall
(n=147)

0.72 (0.20)
75.7 (79.7)

0.79 (0.66)

62 (76.5)

19 (23.5)

81 (92.0)

43.8 (26.5)

46.4 (29.8)

50.5 (30.5)

5.0 (11.3)

16.4 (16.9)

16.5 (17.3)

1.5 (3.1)

2.7 (1.0)

10.5 (8.3)

3.3 (2.4)

4.2 (2.5)

1.9 (0.7)

23 (30.3)

21.1 (16.2)

3.6 (7.1)

2.1 (4.3)

5.5 (10.9)

2.8 (2.3)

9 (10.2)

4.2 (3.9)

19 (21.6)

Continued
(n=88)

TNFi experienced
Discontinued
(n=49)

Overall
(n=171)

Continued
(n=122)

TNFi naive

69 (24.4)

HAQ-S (0–3)

≥30 min

<30 min

 Yes

283 (89.0)

43.9 (29.7)

Patient-reported pain (VAS 0–100)

Morning stiffness, n (%)

46.3 (29.1)

Patient global assessment

4.9 (9.6)

21.4 (21.5)

BSA, % affected

Physician global assessment of psoriasis

2.7 (6.9)
17.1 (15.6)

CRP, mg/L

ESR, mm/hour

2.7 (1.2)

DAS28-CRP

11.2 (9.7)

93 (33.9)

MDA, n (%)¶

CDAI

18.4 (13.9)

 Lateral lumbar flexion (average of right and
left)

 Occiput-to-wall distance

2.1 (4.6)

4.9 (9.2)

Spinal mobility measures, cm

2.5 (2.1)

Tender joint count (0–68)

37 (11.6)

 Dactylitis count (1–20)‡

Dactylitis, n (%)

3.8 (3.3)

73 (23.0)

Characteristic*

 SPARCC Enthesitis Index (1–16)†

Total
population
(N=318)

Continued

0.67 (0.22)
62.0 (19.7)

0.94 (0.70)

41 (80.4)

10 (19.6)

51 (86.4)

53.0 (31.0)**

48.7 (29.4)

54.7 (27.3)

4.6 (9.2)

27.2 (24.6)**

17.1 (12.2)

1.5 (3.4)

2.8 (1.2)

13.5 (10.1)

4.0 (2.8)

4.9 (2.7)

1.9 (0.8)

11 (23.0)

22.3 (18.0)

2.8 (4.2)

2.2 (3.6)

6.1 (8.7)

2.4 (1.5)

7 (11.9)

5.0 (3.9)

19 (32.2)

Discontinued
(n=59)

Table 2 Baseline disease activity and patient-reported outcomes in TNFi-naive and TNFi-experienced patients with PsA overall and in those who continued versus
discontinued their index TNFi by the first follow-up visit
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27.4 (27.8)
35.5 (29.4)

 Work productivity loss (overall work
impairment/absenteeism plus presenteeism)

 Activity impairment

33.2 (29.2)

24.4 (23.2)

21.9 (21.3)

2.6 (7.8)

101 (62.4)

31.1 (28.3)

25.3 (24.4)

22.1 (22.4)

3.1 (8.3)

74 (62.7)

38.4 (31.1)

22.4 (20.3)

21.5 (18.7)

1.6 (6.8)

27 (61.4)

38.1 (29.5)

30.5 (31.8)

27.0 (28.2)

9.8 (24.0)§

87 (61.3)

35.6 (28.1)

26.5 (28.5)

25.5 (27.2)

4.5 (14.3)

55 (65.5)

Continued
(n=88)

Overall
(n=147)

Discontinued
(n=49)

Overall
(n=171)

Continued
(n=122)

TNFi experienced

TNFi naive

41.7 (31.3)

36.0 (35.8)

29.3 (30.0)

17.8 (32.4)

32 (55.2)

Discontinued
(n=59)

*All values were calculated based on available data and are presented as mean (SD) unless otherwise stated and had <20% missing data except for spinal mobility measures, ESR, CRP,
DAS28-CRP, ASDAS-CRP and MDA.
†SPARCC Enthesitis Index among patients with enthesitis.
‡Dactylitis count among patients with dactylitis.
§P<0.05 for the comparison between the overall populations of TNFi-naive and TNFi-experienced patients.
¶MDA was defined as ‘yes’ if a patient met ≥5 of the following seven criteria: tender joint count ≤1, swollen joint count ≤1, BSA ≤3%, patient-reported pain VAS ≤15, patient global activity VAS
≤20, HAQ-S ≤0.5 and tender entheseal points ≤1.
**P<0.05 for the comparison between patients who continued versus discontinued their index TNFi within the TNFi-naive or TNFi-experienced cohort.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis
Functional Index; BSA, body surface area; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, Disease Activity Score in 28 joints with C-reactive protein; EQ-5D,
EuroQol-five dimension; ESR, erythrocyte sedimentation rate; HAQ-S, Health Assessment Questionnaire for the Spondyloarthropathies; MDA, minimal disease activity; PsA, psoriatic
arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; TNFi, tumour necrosis factor inhibitor; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment
questionnaire.

24.3 (24.8)

 Presenteeism (impairment at work/reduced
on-the-job effectiveness)

 Absenteeism (work time missed)

6.1 (17.9)

Current employment, n (%)

WPAI domains, %

188 (61.8)

Characteristic*

Continued
Total
population
(N=318)

Table 2
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Figure 2 Time to discontinuation of the index TNFi in (A) the overall population and (B) TNFi-naive versus TNFi-experienced
patients and time to switch in (C) the overall population and (D) TNFi-naive versus TNFi-experienced patients. TNFi, tumour
necrosis factor inhibitor.

months and 23.0 (15.0) months, respectively. During
follow-up, 75 of 171 TNFi-naive (43.9%) and 80 of 147
TNFi-experienced (54.4%) patients discontinued their
index TNFi, including 33 of 171 (29.3%) and 48 of 147
(32.7%), respectively, who switched to a new biologic.
The overall median time to discontinuation (with or
without switching) was 24 months (95% CI 20 to 28
months) (figure 2A). TNFi-naive patients had a significantly longer time to discontinuation (with or without
switching) compared with TNFi-experienced patients
(median, 27 months (95% CI 22 to 33 months) versus 20
months (95% CI 18 to 28 months); p=0.03) (figure 2B).
Among those who discontinued or switched their index
TNFi, the mean (SD) time to discontinuation or switch
was 14.5 (8.0) months in TNFi-naive patients compared
with 14.0 (8.9) months in TNF-experienced patients.
Due to the low number of switching events (n=81), the
median (95% CI) time to switch to a new biologic could
not be estimated (figure 2C). However, a long-rank test
of the equality of survivor functions between TNFi-naive
and TNFi-experienced patients showed that TNFi-naive
patients had a significantly lower rate of switch compared
with TNFi-experienced patients (p<0.01) (figure 2D).
Among those who switched to a new biologic, the mean
(SD) time to switch was 16.0 (8.1) months in TNFi-naive
patients compared with 13.5 (7.5) months in TNF-experienced patients.
Of the 155 patients who discontinued or switched
their index TNFi, 97 had ≥1 provider-reported reason
for discontinuation or switch (TNFi naive, n=41; TNFi
experienced, n=56). The most commonly reported
Mease PJ, et al. RMD Open 2019;5:e000880. doi:10.1136/rmdopen-2018-000880

reasons for discontinuation or switch of the index TNFi
in both the TNFi-naive and TNFi-experienced cohorts
were lack of efficacy (37/41 (90.2%) and 41/56 (73.2%),
respectively) and side effects (5/41 (12.2%) and 15/56
(26.8%), respectively) (figure 3A).
Characteristics of patients who continued versus
discontinued index TNFi by first follow-up visit
The mean (SD) time to the first follow-up visit was 11.5
(6.7) months (median (IQR), 10.0 (7.0) months). Of
the 155 patients who discontinued or switched their
index TNFi, 108 (69.7%) did so by the first follow-up
visit, including 49 of 75 TNFi-naive (65.3%) and 59 of
80 TNFi-experienced (73.8%) patients. In both the TNFinaive and TNFi experienced cohorts, a higher proportion of patients who discontinued their index TNFi were
female compared with those who continued (62.5% vs
52.5% and 69.0% vs 51.7%, respectively), although this
difference was only statistically significant in the TNFi-experienced cohort (p=0.04) (table 1).
TNFi-naive patients who discontinued their index TNFi
by the first follow-up visit had significantly higher baseline
Clinical Disease Activity Index (CDAI; mean (SD), 14.1
(13.6) vs 9.2 (7.6); p=0.03) and Disease Activity Score in
28 joints with C-reactive protein (DAS28-CRP; mean (SD),
3.5 (1.7) vs 2.4 (1.0); p=0.01) scores compared with those
who continued (table 2). TNFi-naive patients who discontinued their index TNFi by the first follow-up visit also
had a higher tender joint count (mean (SD), 7.3 (13.4) vs
3.0 (4.9)) and lower average lateral lumbar flexion (mean
(SD), 9.8 (13.4) vs 14.7 (4.9) cm) at baseline compared
7
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Figure 3 Provider-reported reasons for discontinuation or switch of the index TNFi in (A) the overall population and (B)
patients who discontinued by the first follow-up visit. Potential reasons for discontinuation or switch included lack of effect
(inadequate response or failure to maintain response), side effects (serious, minor or fear of side effects), social reasons (cost,
patient preference or frequency of administration), doing well (remission or similar events) and other reasons. Patients may
have had more than one reason for discontinuation. TNFi, tumour necrosis factor inhibitor.

with those who continued; however, these differences did
not reach statistical significance (table 2). Differences in
baseline PROs were also observed: TNFi-naive patients
who discontinued their index TNFi by the first follow-up
visit had higher baseline pain (mean (SD), 49.5 (29.8) vs
37.6 (28.9); p=0.02) and patient global assessment (mean
(SD), 48.2 (27.8) vs 38.2 (27.6); p=0.04) scores compared
with those who continued (table 2).
Among TNFi-experienced patients, those who discontinued their index TNFi by the first follow-up visit had
higher baseline physician global assessment (mean (SD),
27.2 (24.6) vs 16.4 (16.9); p=0.01) and fatigue (mean
(SD), 53.0 (31.0) vs 43.8 (26.5); p=0.05) scores compared
with those who continued (table 2). Additionally, TNFi-experienced patients who discontinued their index TNFi by
the first follow-up visit had reported a greater percentage
of work time missed (mean (SD), 17.8% (32.4%) vs 4.5%
(14.3%)) and work productivity loss (mean (SD), 36.0%
(35.8%) vs 26.5% (28.5%)) compared with those who
continued, although these differences did not reach
statistical significance (table 2).
Of the 108 patients who discontinued or switched
their index TNFi by the first follow-up visit, 57 had ≥1
provider-reported reason for discontinuation or switch
(TNFi naive, n=25; TNFi experienced, n=32). The most
commonly reported reasons for discontinuation or switch
in both the TNFi-naive and TNFi-experienced cohorts
were lack of efficacy (16/25 (64.0%) and 18/32 (56.3%),
respectively) and side effects (5/25 (20.0%) and 9/32
(33.3%), respectively) (figure 3B).
Discussion
This real-world study using data from the US-based
Corrona PsA/SpA Registry provides insight into the
persistence and switching of TNFi therapy among TNFinaive versus TNFi-experienced patients with PsA. Patients
who initiated their first TNFi had a longer time to discontinuation and were less likely to switch TNFis compared
8

with those who had previously received ≥1 TNFi. Of
those who discontinued their index TNFi, the majority
discontinued by the first follow-up visit. There was a
trend towards higher baseline disease activity and worse
PROs among patients who discontinued their index
TNFi by the first follow-up visit compared with those who
continued in both the TNFi-naive and TNFi-experienced
cohorts; however, most differences did not reach statistical significance. In both the TNFi-naive and TNFi-experienced groups, the primary provider-reported reasons
for discontinuation or switch of the index TNFi were lack
of effect and side effects, both overall and among patients
who discontinued by the first follow-up visit.
A prior study of patients with PsA enrolled in the
Corrona Registry showed that a higher proportion of
biologic-naive patients were persistent on their TNFi over
4 years of follow-up compared with biologic-experienced
patients and that biologic-naive patients had a longer
time to non-persistence compared with biologic-experienced patients (median, 32 vs 23 months).28 Consistent
with the results of the prior study, TNFi-naive patients in
our study had a longer time to discontinuation (median,
27 vs 20 months) and were less likely to discontinue
or switch biologics compared with TNFi-experienced
patients. However, the median time to TNFi discontinuation was shorter in our study compared with the previous
study. This difference may be due, in part, to differences
between patient populations, including longer disease
duration (mean, 11.2 vs 8.3 years) and higher prevalence of comorbidities (cardiovascular disease, 14.2%
vs 5.4%; cancer, 7.9% vs 4.3%; diabetes mellitus, 13.5%
vs 10.6%) in our study population compared with the
previous study28; a previous study in the DANBIO registry
showed that a greater burden of comorbidities was associated with shorter TNFi persistence.29 Additionally, the
previous study was conducted prior to the approval of
biologics with alternative MOAs for the treatment of PsA;
the approval of new therapies with alternative MOAs has
Mease PJ, et al. RMD Open 2019;5:e000880. doi:10.1136/rmdopen-2018-000880
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provided physicians and patients with a greater number
of treatment options, and recently updated US and European guidelines for the management of PsA reflect the
availability, efficacy and safety of these new biologics.13 14
Current treatment guidelines also recommend using a
treat-to-target-like strategy, when feasible, for the management of PsA, including regular monitoring and adjustment of therapy to achieve disease control.13 14 Together,
these factors may lead to faster cycling of therapies in
patients with an initial inadequate response to a TNFi
in current clinical practice, possibly contributing to the
shorter time to discontinuation observed in our study. Of
note, the current Corrona PsA/SpA Registry collects data
on a number of PsA/SpA-specific disease activity assessments that were not available at the time of the previous
Corrona study. Our results therefore help address a
knowledge gap regarding PsA-specific characteristics of
patients who continue versus discontinue TNFis.
In both the TNFi-naive and TNFi-experienced cohorts
in our study, a higher proportion of patients who discontinued their index TNFi were female compared with those
who continued. Previous studies support the association
of female sex with likelihood of TNFi discontinuation.
Real-world studies in Europe and the USA have shown
that women with PsA are more likely to discontinue TNFi
therapy and have shorter drug survival compared with
men.27 30–32 Additional factors previously found to be
associated with shorter TNFi persistence and increased
likelihood of TNFi discontinuation and switch include
longer disease duration, the presence of other comorbidities, low CRP levels (≤10 mg/L), higher disease activity
as assessed by the CDAI, greater skin involvement and
higher patient global assessment score.28–30 33 In our
study population, there were no significant differences in
disease duration or presence of comorbidities between
patients who continued versus discontinued their index
TNFi in the TNFi-naive or TNFi-experienced cohort. Additionally, there were no significant differences in baseline
CRP levels; however, the overall CRP levels in all groups
were <10 mg/L at baseline. TNFi-naive patients who
discontinued their index TNFi by the first follow-up visit
had significantly higher baseline CDAI and DAS28-CRP
scores compared with those who continued. There was
a trend towards higher CDAI and other disease activity
measures at baseline among TNFi-experienced patients
who discontinued their index TNFi compared with those
who continued, although these differences did not reach
statistical significance. Additionally, patients who discontinued their index TNFi had higher pain and patient
global assessment scores at baseline compared with those
who continued; these differences were statistically significant in the TNFi-naive cohort. Differences in patient
characteristics associated with TNFi discontinuation in
our study versus previous studies may be due, in part, to
differences among study populations with respect to age,
disease duration, comorbidities and/or baseline disease
activity.
Mease PJ, et al. RMD Open 2019;5:e000880. doi:10.1136/rmdopen-2018-000880

This study is subject to the general limitations of realworld observational studies. A general concern is that
patients enrolled in registries may not be representative
of patients seen elsewhere in general practice. Patients
in this study are routinely seen and treated by rheumatologists voluntarily participating in the Corrona
PsA/SpA Registry and may not be representative of all
patients with PsA in the USA. In addition, the small
sample size may have limited the ability to detect statistically significant differences in baseline characteristics,
disease activity measures and PROs between patients
who continued versus discontinued their index TNFi by
the first follow-up visit. Sample size considerations also
necessitated the pooling of TNFis for analysis; thus, no
conclusions can be drawn regarding the persistence or
rate of switch of any specific TNFi among patients with
PsA. Analyses of discontinuation and switching were not
adjusted for differences in patient characteristics, and
no conclusions can be drawn regarding characteristics
predictive of TNFi discontinuation. Finally, only half
of patients who discontinued their index TNFi by the
first follow-up visit (57/108) and 60% of patients who
discontinued overall had provider-reported reasons for
discontinuation, which limits insight into the reasons for
discontinuation or switch of TNFis in TNFi-naive versus
TNFi-experienced patients.
In this real-world analysis of US patients with PsA,
TNFi-experienced patients were more likely to discontinue or switch their index TNFi and had a shorter time
to discontinuation compared with TNFi-naive patients.
Patients who discontinued by the first follow-up visit
were more likely to be female compared with those who
continued, and there was a trend towards higher disease
activity and worse pain and patient global assessment
scores among patients who discontinued compared with
those who continued. The most commonly reported
reasons for discontinuation or switch of the index TNFi
among both TNFi-naive and TNFi-experienced patients
were lack of effect and side effects. These results may
help inform treatment decisions when selecting later
lines of therapy for patients with PsA.
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